Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).

[1]  C. Denkert,et al.  Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer , 2018, Neoplasia.

[2]  T. Walsh,et al.  Mutations in Homologous Recombination Genes and Outcomes in Ovarian Carcinoma Patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study , 2017, Clinical Cancer Research.

[3]  R. Burger,et al.  Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses , 2017, Journal of the National Cancer Institute.

[4]  R. Bourgon,et al.  156PDTargeted NGS profiling identifies genomic alterations associated with high-risk eBC , 2017 .

[5]  Qinghua Zhou,et al.  Microvessel density as a prognostic factor in esophageal squamous cell cancer patients , 2017, Medicine.

[6]  H. Gabra,et al.  Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium. , 2017, European journal of cancer.

[7]  A. Reuss,et al.  Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Mallika Pal,et al.  VEGF Expression to Support Targeted Therapy in Ovarian Surface Epithelial Neoplasms. , 2017, Journal of clinical and diagnostic research : JCDR.

[9]  G. Rossi,et al.  Bronchial fibroepithelial polyp: a clinico‐radiologic, bronchoscopic, histopathological and in‐situ hybridisation study of 15 cases of a poorly recognised lesion , 2017, The clinical respiratory journal.

[10]  Y. Feng,et al.  Roles of PECAM-1 in cell function and disease progression. , 2016, European review for medical and pharmacological sciences.

[11]  Zhenfeng Zhang,et al.  A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis , 2016, Scientific Reports.

[12]  P. Newman,et al.  Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31) , 2016, Current opinion in hematology.

[13]  V. Beral,et al.  Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer , 2015, Nature Reviews Cancer.

[14]  E. Partridge,et al.  Molecular Mechanism Linking BRCA1 Dysfunction to High Grade Serous Epithelial Ovarian Cancers with Peritoneal Permeability and Ascites. , 2015, Journal of gynecology research.

[15]  Lei He,et al.  Microvessel density as a prognostic factor in ovarian cancer: a systematic review and meta-analysis. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[16]  E. Kohn,et al.  Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. , 2014, The Lancet. Oncology.

[17]  Yuquan Wei,et al.  Intratumoral vessel density as prognostic factors in head and neck squamous cell carcinoma: A meta‐analysis of literature , 2014, Head & neck.

[18]  A. Reuss,et al.  Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Azzi,et al.  Vascular Permeability and Drug Delivery in Cancers , 2013, Front. Oncol..

[20]  M. Clément,et al.  An immunologist's guide to CD31 function in T-cells , 2013, Journal of Cell Science.

[21]  Brian J. Smith,et al.  Microvessel density and p53 mutations in advanced-stage epithelial ovarian cancer. , 2013, Cancer letters.

[22]  Jinke Li,et al.  The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. , 2013, Gynecologic oncology.

[23]  A. Paradiso,et al.  Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer , 2012, European Journal of Human Genetics.

[24]  G. Coukos,et al.  Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. , 2012, Gynecologic oncology.

[25]  Gord Glendon,et al.  Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer , 2012 .

[26]  B. Monk,et al.  Incorporation of bevacizumab in the primary treatment of ovarian cancer. , 2011, The New England journal of medicine.

[27]  E. Vallikad,et al.  Ovarian Serous Carcinoma: Relationship of p53 and bcl-2 With Tumor Angiogenesis and VEGF Expression , 2011, International Journal of Gynecological Pathology.

[28]  K. Hess,et al.  Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. , 2011, JAMA.

[29]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[30]  J. Yi,et al.  OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[32]  D. Alberts,et al.  Clinical Trials in Recurrent Ovarian Cancer , 2011, International Journal of Gynecologic Cancer.

[33]  R. Drapkin,et al.  New insights into the pathogenesis of serous ovarian cancer and its clinical impact. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  B. Uzzan,et al.  Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. , 2004, Cancer research.

[35]  Brian J. Smith,et al.  The influence of microvessel density on ovarian carcinogenesis. , 2003, Gynecologic oncology.

[36]  A. Sood,et al.  Ovarian cancer p53 mutation is associated with tumor microvessel density. , 2002, Gynecologic oncology.

[37]  T. Hamilton,et al.  Vascular endothelial growth factor in ovarian cancer , 1999, Current oncology reports.

[38]  D. Sherer,et al.  Angiogenesis in malignancies of the female genital tract. , 1999, Gynecologic oncology.

[39]  N. Weidner.  Intratumor microvessel density as a prognostic factor in cancer. , 1995, The American journal of pathology.

[40]  H. Dvorak,et al.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. , 1983, Science.

[41]  E. Berns,et al.  Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. , 2016, European journal of cancer.

[42]  A. Sood,et al.  Targeting the Tumor Microenvironment in Ovarian Cancer , 2016 .

[43]  B. Kong,et al.  Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. , 2012, Journal of hematology & oncology.

[44]  B. Kong,et al.  Ovarian serous carcinoma : recent concepts on its origin and carcinogenesis , 2012 .

[45]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.